New nanobodies to fight SARS-CoV-2 and other coronaviruses
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses
This study is working on new tiny antibodies that could help stop and treat infections from COVID-19 and similar viruses by targeting a key part of the virus, and if successful, these could be helpful for patients dealing with these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10662297 on NIH RePORTER |
What this research studies
This research focuses on developing novel nanobodies that can prevent and treat infections caused by SARS-CoV-2 and other pathogenic coronaviruses. The approach involves targeting specific proteins on the virus, particularly the spike protein, which is crucial for the virus's ability to enter human cells. By creating nanobodies that can bind to these proteins, the research aims to elicit strong immune responses and neutralize the virus. Patients may benefit from these new therapeutic agents if they are effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit include individuals at high risk for severe COVID-19, such as those with underlying health conditions or compromised immune systems.
Not a fit: Patients who are not infected with coronaviruses or those who do not have risk factors for severe disease may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively prevent or reduce the severity of COVID-19 and other coronavirus infections.
How similar studies have performed: Other research has shown promise in using nanobodies for therapeutic purposes, indicating that this approach could be effective.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Du, Lanying — Georgia State University
- Study coordinator: Du, Lanying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.